Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin-Reference-Cited by-同舟云学术

Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin

Published:2012-04-23 Issue:10 Volume:110 Page:1478-1484
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:

Author:

Saito Kazutaka,Urakami Shinji,Komai Yoshinobu,Yasuda Yosuke,Kubo Yuichi,Kitsukawa Shinichi,Okubo Yuhei,Yamamoto Shinya,Yonese Junji,Fukui Iwao

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2012.11153.x/fullpdf

Reference26 articles.

1. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors;Logothetis;J Clin Oncol,1990

2. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study;Saxman;J Clin Oncol,1997

3. Combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin for metastatic urothelial cancer;Fukui;Cancer Chemother Pharmacol,2001

4. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer;Moore;J Clin Oncol,1997

5. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer;Stadler;J Clin Oncol,1997

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2024-05

2. Simple predictors for the completion of scheduled gemcitabine‑cisplatin regimens based on real‑world urothelial cancer data;Molecular and Clinical Oncology;2024-04-01

3. Prognostic model using postoperative normalization of C-reactive protein levels in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy;Canadian Urological Association Journal;2023-11-23

4. Site-Specific Differences in PD-1 Blockade Success and Biomarkers in Urothelial Carcinoma Treated with Pembrolizumab;Clinical Genitourinary Cancer;2023-02

5. C‐reactive protein as a prognostic predictor for non‐muscle invasive bladder cancer after intravesical bacillus Calmette‐Guérin therapy: A Japan Urological Oncology Group study analysis;International Journal of Urology;2022-11-30